Transgenic mice containing FPR-RS4 gene disruptions
OwnerKeith D. Allen, Mark Moore +1inventors
InventorsKeith D. Allen, Mark Moore, William Matthews
Life of this patent
Estimating the term…
Abstract
The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in an FPR-RS4 gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
Claims34
A targeting construct comprising:
- (a) a first polynucleotide sequence homologous to at least a first portion of an FPR-RS4 gene;
- (b) a second polynucleotide sequence homologous to at least a second portion of the FPR-RS4 gene;
- and
- (c) a selectable marker.
A method of producing a targeting construct, the method comprising:
- (a) providing a first polynucleotide sequence homologous to at least a first portion of an FPR-RS4 gene;
- (b) providing a second polynucleotide sequence homologous to at least a second portion of the FPR-RS4 gene;
- (c) providing a selectable marker;
- and
- (d) inserting the first sequence, second sequence, and selectable marker into a vector to produce the targeting construct.
A cell comprising a disruption in an FPR-RS4 gene.
A non-human transgenic animal comprising a disruption in an FPR-RS4 gene.
A method of identifying an agent that modulates the expression or function of an FPR-RS4 gene, the method comprising:
- (a) providing a non-human transgenic animal comprising a disruption in an FPR-RS4 gene;
- (b) administering an agent to the non-human transgenic animal;
- and
- (c) determining whether the expression or function of the disrupted FPR-RS4 gene in the non-human transgenic animal is modulated.
A method of identifying an agent that modulates the expression or function of an FPR-RS4 gene, the method comprising:
- (a) providing a cell comprising a disruption in an FPR-RS4 gene;
- (b) contacting the cell with the agent;
- and
- (c) determining whether the expression or function of the FPR-RS4 gene is modulated.
A transgenic mouse comprising a disruption in an FPR-RS4 gene, wherein there is no significant expression of the FPR-RS4 gene in the transgenic mouse.
A transgenic mouse comprising a homozygous disruption in an FPR-RS4 gene, wherein the transgenic mouse exhibits increased anxiety.
A transgenic mouse comprising a homozygous disruption in an FPR-RS4 gene, wherein the transgenic mouse exhibits impaired motor coordination or balance or ataxia.
A transgenic mouse comprising a homozygous disruption in an FPR-RS4 gene, wherein the transgenic mouse exhibits a decreased susceptibility to seizure.
A method of identifying an agent that ameliorates a phenotype associated with a disruption in an FPR-RS4 gene, the method comprising:
- (a) administering an agent to a transgenic mouse comprising a disruption in an FPR-RS4 gene;
- and
- (b) determining whether the agent ameliorates at least one of the following phenotypes:
- increased anxiety, impaired motor coordination or balance, ataxia, or decreased susceptibility to seizure.
An agonist or antagonist of FPR-RS4.
Phenotypic data associated with a transgenic mouse comprising a disruption in an FPR-RS4 gene, wherein the phenotypic data is in an electronic database.
A method of treating anxiety, the method comprising administering to a subject in need a therapeutically effective amount of FPR-RS4.
A method of treating impaired motor coordination, impaired balance, or ataxia, the method comprising administering to a subject in need a therapeutically effective amount of FPR-RS4.
A method of identifying an agent that inhibits the activity or function of FPR-RS4, the method comprising:
- (a) providing a cell expressing FPR-RS4;
- (b) contacting the cell with an agent;
- and
- (c) determining whether the agent inhibits the activity or function of FPR-RS4, wherein the agent has an affect on seizure susceptibility.
A pharmaceutical composition comprising a FPR-RS4 protein.
Dependencies are inferred from the claim text.